PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Princeton, New Jersey.…
PMV Pharmaceuticals Reports Third Quarter 2026 Financial Results and Corporate Highlights
PMV Pharmaceuticals (NASDAQ: PMVP) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 54 employees.
The shares were at 0.8760 USD on 20 November 2026, down 29.9% over 52 weeks. Its 52-week range is 0.6600 USD to 1.910 USD: the price is 54.1% below the high and 32.7% above the low.
Its market capitalisation is 66.17M USD.
PMV Pharmaceuticals reports return on equity of -74.2% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 102.42M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 4 March 2027.